




RealRate

PHARMACEUTICAL 2021

Intercept Pharmaceuticals INC
Rank 341 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intercept Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intercept Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 5.8% points. The greatest weakness of Intercept Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 125% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	545,741
Cost of Goods Sold	5,322
Intangible Assets	0
Liabilities, Current	179,076
Liabilities, Non-Current	568,266
Other Assets	28,422
Other Compr. Net Income	-1,333
Other Expenses	14,630
Other Liabilities	0
Other Net Income	-43,640
Other Revenues	312,690
Property and Equipment	6,326
Research and Development	191,485
Selling, General and Administrative Expense	332,493

Output Variable	Value in 1000 USD
Assets	580,489
Liabilities	747,342
Expenses	543,930
Revenues	312,690
Stockholders Equity	-166,853
Net Income	-274,880
Comprehensive Net Income	-275,546
BaseVar	1,114,712
ECR before LimitedLiability	-96%
Economic Capital Ratio	131%